A Study of TAK-279 in Adults With or Without Liver Damage
NCT05976321
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
27
Enrollment
INDUSTRY
Sponsor class
Conditions
Hepatic Impairment
Healthy Volunteers
Interventions
DRUG:
TAK-279
Sponsor
Takeda